Browsing ICR Divisions by author "Pawlyn, Charlotte"
Now showing items 21-36 of 36
-
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Panopoulou, A; Cairns, DA; Holroyd, A; Nichols, I; Cray, N; et al. (AMER SOC HEMATOLOGY, 2023-04-06)Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in ... -
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn, C; Bright, MD; Buros, AF; Stein, CK; Walters, Z; et al. (SPRINGERNATURE, 2017-03-31)Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly ... -
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Davies, FE; Pawlyn, C; Usmani, SZ; San-Miguel, JF; Einsele, H; et al. (AMER ASSOC CANCER RESEARCH, 2022-07-06)The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in ... -
Physicians, paraproteins and progress: diagnosis and management of myeloma.
Pawlyn, C; Jackson, GH (MA HEALTHCARE LTD, 2019-02-02)Myeloma outcomes have improved dramatically over the last decade as a result of novel therapies, several of which are now commonly continued to disease relapse. Physicians who do not work in haematology are therefore more ... -
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah, V; Sherborne, AL; Walker, BA; Johnson, DC; Boyle, EM; et al. (NATURE PUBLISHING GROUP, 2018-01-01)Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) ... -
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
Mian, H; McCurdy, A; Giri, S; Grant, S; Rochwerg, B; et al. (SPRINGERNATURE, 2023-01-05)Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults. Several frailty tools have been developed to address the heterogeneity of aging in this population. Uptake of these measures has been ... -
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou, C; Porta, N; Sharma, B; Levine, D; Koh, D-M; et al. (RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2021-09-01)Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, ... -
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
Ludwig, H; Boccadoro, M; Moreau, P; San-Miguel, J; Cavo, M; et al. (SPRINGERNATURE, 2020-08-19)Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections ... -
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Bird, S; Panopoulou, A; Shea, RL; Tsui, M; Saso, R; et al. (ELSEVIER SCI LTD, 2021-05-25) -
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (ELSEVIER SCI LTD, 2019-12-01)BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents ... -
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones, JR; Cairns, DA; Gregory, WM; Collett, C; Pawlyn, C; et al. (NATURE PUBLISHING GROUP, 2016-12-09)We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary ... -
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Jenner, MW; Pawlyn, C; Davies, FE; Menzies, T; Hockaday, A; et al. (WILEY, 2022-12-21)Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The 'Myeloma XI' trial, ... -
The genomic landscape of plasma cells in systemic light chain amyloidosis.
Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; et al. (AMER SOC HEMATOLOGY, 2018-12-27) -
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
Pawlyn, C; Cairns, D; Kaiser, M; Striha, A; Jones, J; et al. (NATURE PUBLISHING GROUP, 2020-02-01)Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with ... -
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.
Pawlyn, C; Kaiser, MF; Heuck, C; Melchor, L; Wardell, CP; et al. (AMER ASSOC CANCER RESEARCH, 2016-12-01)PURPOSE: Epigenetic dysregulation is known to be an important contributor to myeloma pathogenesis but, unlike other B-cell malignancies, the full spectrum of somatic mutations in epigenetic modifiers has not been reported ... -
Toward personalized treatment in multiple myeloma based on molecular characteristics.
Pawlyn, C; Davies, FE (AMER SOC HEMATOLOGY, 2019-02-14)To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The widespread evolution, validation, and clinical utilization of molecular ...